Aquestive to present Anaphylm data at AAAAI: symptom resolution in 12 min, stable under extreme conditions

Aquestive Therapeutics, Inc.

Median symptom resolution time 12 min vs 74 min without treatment; mean angioedema resolution within 5 min.
Anaphylm matched or exceeded IM epinephrine in all key PK parameters in Phase 2 OASIS study.
Stability and potency maintained under extreme heat, freezing, and water submersion.
Presentations at AAAAI Annual Meeting Feb 28 – Mar 3, 2025 in San Diego.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.